TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15725138

Group type: EXPERIMENTAL
Intervention: Chest tube removal at 24 hours (Group A)
Number of subjects: 83
Study: 11888973

Group type: EXPERIMENTAL
Intervention: Endotracheal tube for intermittent subglottic secretions drainage
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard endotracheal tube
Number of subjects: 150
Study: 10443663

Group type: EXPERIMENTAL
Intervention: Leuprolide with vitamin K2 (group B)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Leuprolide with 1,25‐(OH)2D3 (group C)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Leuprolide with vitamin K2 and 1,25‐(OH)2D3 (group D)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Leuprolide only (group A)
Number of subjects: 110
Study: 8666860

Group type: COMPARATOR
Intervention: 300 mg aerosolized pentamidine (AP) once-monthly
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 300 mg aerosolized pentamidine (AP) twice-monthly
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 205
Study: 2134327

Group type: EXPERIMENTAL
Intervention: IdB 1027 (600 mg b.i.d.) for 10 days
Number of subjects: 8
Study: 7356895

Group type: EXPERIMENTAL
Intervention: Intravenous disopyramide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral disopyramide
Number of subjects: 8
Study: 31325212

Group type: EXPERIMENTAL
Intervention: JR-131
Number of subjects: 334

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 334
Study: 30892810

Group type: EXPERIMENTAL
Intervention: 2RDA (1.6 g kg‐1 day‐1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: RDA (0.8 g kg‐1 day‐1)
Number of subjects: 31
Study: 27329344

Group type: EXPERIMENTAL
Intervention: Pay-for-performance intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no incentives)
Number of subjects: 0
Study: 25794201

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided greater occipital nerve block (GONB) with bupivacaine 0.5% (1.5 mL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (normal saline 0.9% 1.5 mL)
Number of subjects: 32
Study: 24437202

Group type: EXPERIMENTAL
Intervention: Ozonotherapy and klimadynon (herbal medicine with estrogen-like action)
Number of subjects: 0
Study: 21719111

Group type: EXPERIMENTAL
Intervention: 35% carbon dioxide exposure
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo room air
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adjunctive clonazepam
Number of subjects: 8
Study: 19301038

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevelamer therapy
Number of subjects: 60
Study: 17525363

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: UFH+eptifibatide
Number of subjects: 0
Study: 16182977

Group type: EXPERIMENTAL
Intervention: Septic shock group (n=72)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Severe sepsis group (n=56)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Sepsis group (n=54)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis
Number of subjects: 182
Study: 12888182

Group type: EXPERIMENTAL
Intervention: S100B serum concentrations in patients with major depression
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: S100B serum concentrations
Number of subjects: 25
Study: 10570386

Group type: EXPERIMENTAL
Intervention: Low-dose narrow-band UVB phototherapy with calcipotriol ointment (50 microg/g) applied twice daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Low-dose narrow-band UVB phototherapy without calcipotriol ointment
Number of subjects: 53
Study: 8673999

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (AI) with tumor-infiltrating lymphocytes (TIL) and recombinant interleukin-2 (rIL-2)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (AI)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy
Number of subjects: 113
Study: 1651060

Group type: EXPERIMENTAL
Intervention: Pentostam (20 mg Sb/kg/day intramuscularly for 20 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Allopurinol ribonucleoside (1,500 mg QID) plus probenecid (500 mg QID) for 28 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 61
Study: 7044709

Group type: EXPERIMENTAL
Intervention: Prednisone treatment group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 25
Study: 30938155

Group type: EXPERIMENTAL
Intervention: Visible-light-sensitive azo-dye and mesogenic acrylate doped to host liquid crystals, stabilized by unpolarized UV-light irradiation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reactive mesogens (RMs) in an LC host photopolymerized into thin interfacial layers.
Number of subjects: 0
Study: 27630010

Group type: EXPERIMENTAL
Intervention: Fast eating (within 5 minutes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Slow eating (within 30 minutes)
Number of subjects: 26
Study: 25669614

Group type: EXPERIMENTAL
Intervention: L-Polamidon® 5 mg tablets (test)
Number of subjects: 33

Group type: COMPARATOR
Intervention: L-Polamidon® solution for substitution (reference)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Test/Reference (T/R) adjusted geometric mean ratios
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adverse Events
Number of subjects: 33
Study: 24393008

Group type: EXPERIMENTAL
Intervention: Acetate-containing bicarbonate dialysate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetate-free dialysate
Number of subjects: 0
Study: 21898754

Group type: EXPERIMENTAL
Intervention: Oral anti-diabetes drugs + basal insulin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Oral anti-diabetes drugs alone
Number of subjects: 129
Study: 18977068

Group type: EXPERIMENTAL
Intervention: Pitavastatin (P) therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 32
Study: 17342426

Group type: EXPERIMENTAL
Intervention: Depth of embryo transfer > 10 < 15 mm (group A)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Depth of embryo transfer <= 10 mm (group B)
Number of subjects: 104
Study: 16680621

Group type: EXPERIMENTAL
Intervention: First randomization strategy using 35-word lists based on recognition performance at each S/B ratio
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Second randomization strategy using 35-word lists based on recognition performance only
Number of subjects: 120
Study: 11965204

Group type: EXPERIMENTAL
Intervention: Tobacco use (cigarette, cigar, or pipe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Former tobacco use
Number of subjects: 0
Study: 9862541

Group type: EXPERIMENTAL
Intervention: Wheelchair basketball players
Number of subjects: 23

Group type: COMPARATOR
Intervention: Spinal cord‐injured persons
Number of subjects: 23
Study: 7619664

Group type: EXPERIMENTAL
Intervention: desipramine 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: reboxetine 4 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 2228340

Group type: EXPERIMENTAL
Intervention: Digoxin (mean maintenance daily dose of 0.30 +/- 0.03 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 34
Study: 154426

Group type: EXPERIMENTAL
Intervention: Oxamethacin (100 mg b.i.d.)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Indomethacin (50 mg b.i.d.)
Number of subjects: 525
Study: 30573506

Group type: EXPERIMENTAL
Intervention: Mogamulizumab 1.0 mg/kg once weekly for 4 weeks and biweekly thereafter
Number of subjects: 71

Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy
Number of subjects: 71
Study: 27028701

Group type: EXPERIMENTAL
Intervention: Free preventive checkup with a qualified doctor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 25782428

Group type: EXPERIMENTAL
Intervention: 40 g soy flour (whole soy group)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Number of subjects: 270

Group type: COMPARATOR
Intervention: 40 g low-fat milk powder (active control group)
Number of subjects: 270
Study: 23562197

Group type: EXPERIMENTAL
Intervention: MFNS + OXY3 (200 μg MFNS q.d. + 3 sprays/nostril of OXY 0.05%)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: MFNS + OXY1 (200 μg MFNS q.d. + 1 spray/nostril of OXY)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: OXY b.i.d.
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: MFNS q.d.
Number of subjects: 705
Study: 19491907

Group type: EXPERIMENTAL
Intervention: Complementary and alternative therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Report from a UK-based arthritis charity
Number of subjects: 0
Study: 17711659

Group type: EXPERIMENTAL
Intervention: Transcoronary ablation of septal hypertrophy (TASH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dual-chamber cardiac pacing (PM)
Number of subjects: 23
Study: 15226336

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDPEB) 40 mg/m² on days 1 through 5
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard-dose cisplatin (PEB) 20 mg/m² on days 1 through 5
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDPEB)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard-dose cisplatin (PEB)
Number of subjects: 299
Study: 11477498

Group type: EXPERIMENTAL
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 9352990

Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 19
Study: 8176150

Group type: EXPERIMENTAL
Intervention: CGA consultation
Number of subjects: 3593

Group type: COMPARATOR
Intervention: Usual care by the attending physician
Number of subjects: 3593
Study: 3312225

Group type: EXPERIMENTAL
Intervention: Contralateral carotid arterial stenoses greater than 50%
Number of subjects: 333

Group type: COMPARATOR
Intervention: Less severe contralateral carotid arterial stenoses
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Presence of significant contralateral disease
Number of subjects: 333
Study: 30084517

Group type: EXPERIMENTAL
Intervention: VBN+
Number of subjects: 100

Group type: COMPARATOR
Intervention: VBN-
Number of subjects: 100
Study: 27196121

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg∙kg‐1)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 25622776

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone and counseling
Number of subjects: 353
Study: 22614545

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (Bup-SR) for 8 weeks
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 248
Study: 20921084

Group type: EXPERIMENTAL
Intervention: Oxygenator with high-resistance and low-compliance (Group 1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxygenator with low-resistance and high-compliance (Group 2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-resistance oxygenator (Group 2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both oxygenators
Number of subjects: 23
Study: 18349557

Group type: EXPERIMENTAL
Intervention: Standard 1-week triple therapy followed by omeprazole (20 mg, qd) for 3 weeks (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard 1-week triple therapy only (group B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg, qd) for 3 weeks followed by 1-week triple therapy (group C)
Number of subjects: 28
Study: 17201236

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 14696468

Group type: EXPERIMENTAL
Intervention: Low-dose anticancer drugs (Group A, n = 40)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional-dose anticancer drugs (Group B, n = 42)
Number of subjects: 82
Study: 9876959

Group type: EXPERIMENTAL
Intervention: eptastigmine 15 mg t.i.d.
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: eptastigmine 10 mg t.i.d.
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: eptastigmine (both doses) in severely impaired patients (n=222)
Number of subjects: 320

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 320
Study: 7907054

Group type: EXPERIMENTAL
Intervention: PGE2 tablets (n = 106)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Artificial rupture of membranes only (n = 103)
Number of subjects: 209
Study: 2685984

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 138
Study: 828848

Group type: EXPERIMENTAL
Intervention: Ibuprofen (Motrin)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 78
Study: 28324091

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 51596

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 51596
Study: 26698250

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine with dexmedetomidine (group D)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine only (group P)
Number of subjects: 52
Study: 23810264

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) plus feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video information (VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Informational brochure (IB)
Number of subjects: 0
Study: 19405015

Group type: EXPERIMENTAL
Intervention: Continuous treatment with infliximab (administered at weeks 4, 6, 10, and then every 6 weeks)
Number of subjects: 158

Group type: COMPARATOR
Intervention: On-demand treatment with infliximab (administered at weeks 4, 6, 10 and then upon symptom recurrence)
Number of subjects: 158
Study: 17316832

Group type: EXPERIMENTAL
Intervention: Ciprodex (ciprofloxacin 0.3%/dexamethasone 0.1%) for 5 days post-operatively
Number of subjects: 200

Group type: COMPARATOR
Intervention: No treatment for 5 days post-operatively
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ciprodex treatment
Number of subjects: 200
Study: 15549681

Group type: EXPERIMENTAL
Intervention: Audiovisual /bi/ and audio /bi/‐visual /vi/ habituation in female infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mismatched audio /bi/‐visual /vi/ habituation in male infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concordant /bi/‐/bi/ versus /vi/‐/vi/ displays testing
Number of subjects: 0
Study: 11369837

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 14

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 14
Study: 9645872

Group type: EXPERIMENTAL
Intervention: Chloroquine (300 mg base weekly)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Primaquine (0.5 mg base/kg daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 7837323

Group type: EXPERIMENTAL
Intervention: i.v. Tramadol (1 mg/Kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (20 ml) - Control group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 2967164

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined beta‐agonist and anticholinergic preparation (fenoterol hydrobromide 200 micrograms and ipratropium bromide 80 micrograms)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31533666

Group type: EXPERIMENTAL
Intervention: Community-wide mass deworming with albendazole alongside school-based deworming
Number of subjects: 64

Group type: COMPARATOR
Intervention: School-based targeted deworming with albendazole
Number of subjects: 64
Study: 29187242

Group type: EXPERIMENTAL
Intervention: Therapeutic cooling plus best medical treatment
Number of subjects: 800

Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 800
Study: 26637673

Group type: EXPERIMENTAL
Intervention: Cementless femoral component
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cemented femoral component
Number of subjects: 120
Study: 23646840

Group type: EXPERIMENTAL
Intervention: Favorable binge drinker stereotypes
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Implementation intentions geared at increasing self-focused attention
Number of subjects: 755
Study: 21334442

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (waiting period)
Number of subjects: 0
Study: 19799020

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (conventional therapy only)
Number of subjects: 78
Study: 16407007

Group type: EXPERIMENTAL
Intervention: Ureteroscopic laser endopyelotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acucise endopyelotomy
Number of subjects: 40
Study: 15581190

Group type: EXPERIMENTAL
Intervention: Hyperarticulation of vowels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification and rating of each stimulus
Number of subjects: 0
Study: 11526772

Group type: EXPERIMENTAL
Intervention: Laparoscopic marsupialisation of endometrial cyst and coagulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stripping of lining
Number of subjects: 20
Study: 9425972

Group type: EXPERIMENTAL
Intervention: Mepivacaine (1.4 mg/kg in 40 mL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study: 8075912

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168
Study: 3631787

Group type: EXPERIMENTAL
Intervention: Neurobehavioral Cognitive Status Examination (NCSE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cognitive Capacity Screening Examination (CCSE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 30
Study: 31524780

Group type: EXPERIMENTAL
Intervention: CON + BFR
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ECC + BFR
Number of subjects: 17

Group type: COMPARATOR
Intervention: CON
Number of subjects: 17

Group type: COMPARATOR
Intervention: ECC
Number of subjects: 17
Study: 30043250

Group type: EXPERIMENTAL
Intervention: Item response theory (IRT) based approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Headache scores at 4 h post-dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Headache scores at 2 h post-dose
Number of subjects: 0
Study: 26329035

Group type: EXPERIMENTAL
Intervention: Technique video demonstration
Number of subjects: 100
Study: 24364989

Group type: EXPERIMENTAL
Intervention: Doctor-mask wearing consultations
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Non-mask wearing consultations
Number of subjects: 1030
Study: 21422729

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 17804774

Group type: EXPERIMENTAL
Intervention: RF 2000 device
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RF 3000 device
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RITA device
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Internally cooled electrode device
Number of subjects: 100
Study: 15352918

Group type: EXPERIMENTAL
Intervention: Amitriptyline (80 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9440422

Group type: EXPERIMENTAL
Intervention: 4 km/h speed change
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 8 km/h speed change
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison between 4 km/h and 8 km/h
Number of subjects: 42
Study: 8304306

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine at 8:30 AM
Number of subjects: 16

Group type: COMPARATOR
Intervention: 40 mg famotidine at 10 PM
Number of subjects: 16
Study: 2724250

Group type: EXPERIMENTAL
Intervention: 5 mg/m2 oral weekly methotrexate (MTX)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 10 mg/m2 oral weekly methotrexate (MTX)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 46
Study: 31345271

Group type: EXPERIMENTAL
Intervention: Screening for juvenile idiopathic arthritis (JIA) using the Early Diagnosis of Chronic Arthritis - 12 items (EDA-12) questionnaire.
Number of subjects: 5710

Group type: EXPERIMENTAL
Intervention: Prevalence of JIA in the studied population.
Number of subjects: 5710
Study: 29390150

Group type: EXPERIMENTAL
Intervention: RV1 (monovalent rotavirus vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No RV1 (unvaccinated nonsecretors)
Number of subjects: 0
Study: 27451396

Group type: EXPERIMENTAL
Intervention: Combined method (direct measurements of spilled blood, sucker bottle volumes, weighing of surgical towels and drapes)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Hemoglobin level calculation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Surgeon's estimation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Anesthesiologists' estimation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Visual assessment by anesthesiologists
Number of subjects: 156
Study: 24675993

Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (E-Lock)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional catheter-care (CCC)
Number of subjects: 200
Study: 22521298

Group type: EXPERIMENTAL
Intervention: Educational intervention promoting healthy dietary habits and increasing physical activity through the IVAC pedagogy applied over 2 school years (2006-2008)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20558502

Group type: EXPERIMENTAL
Intervention: Sativex (nabiximols)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666